Suppr超能文献

美国癌症联合委员会(AJCC)IVc期鼻咽癌中的寡转移:总生存期较好的一个亚组。

Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: A subset with better overall survival.

作者信息

Tian Yun-Hong, Zou Wen-Hui, Xiao Wei-Wei, Zeng Lei, Yuan Xia, Bai Li, Lu Taixiang, Tian Yunming, Han Fei

机构信息

Department of Radiation Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, China.

Department of Radiation Oncology, Hui Zhou Municipal Central Hospital, Guangzhou, China.

出版信息

Head Neck. 2016 Aug;38(8):1152-7. doi: 10.1002/hed.24345. Epub 2016 May 24.

Abstract

BACKGROUND

The purpose of this study was to analyze the patterns of metastasis and therapeutic approaches in American Joint Committee on Cancer (AJCC) stage IVc nasopharyngeal carcinoma (NPC).

METHODS

A retrospective analysis of 263 patients with stage IVc NPC revealed the incidence of bone, liver, and lung metastases was 67.7%, 32.3%, and 16.0%, respectively. All patients received chemotherapy; 160 patients received radiotherapy (RT) to the primary tumor.

RESULTS

The factors associated with poor overall survival (OS) were Karnofsky Performance Scale (KPS) ≤70, liver metastasis, multiple-organ metastasis, ≥6 lesions, no RT to the primary tumor, and <4 chemotherapy cycles. Two subgroups of M1 disease were divided into: M1a (oligometastases) = single-organ metastases or 1 to 5 lesions; and M1b = multiple-organ metastases or ≥6 lesions. The 5-year OS rates for M1a and M1b were 38.7% versus 7.0%, respectively.

CONCLUSION

Patients with oligometastases have significantly better OS than patients with widespread metastases. Long-term disease-free survival can be achieved in selected patients with oligometastases after systemic chemotherapy and definitive RT. © 2016 Wiley Periodicals, Inc. Head Neck 38:1152-1157, 2016.

摘要

背景

本研究旨在分析美国癌症联合委员会(AJCC)IVc期鼻咽癌(NPC)的转移模式及治疗方法。

方法

对263例IVc期鼻咽癌患者进行回顾性分析,结果显示骨转移、肝转移和肺转移的发生率分别为67.7%、32.3%和16.0%。所有患者均接受了化疗;160例患者对原发肿瘤进行了放疗(RT)。

结果

与总生存期(OS)较差相关的因素包括卡诺夫斯基功能状态评分(KPS)≤70、肝转移、多器官转移、≥6个病灶、未对原发肿瘤进行放疗以及化疗周期<4个。M1期疾病分为两个亚组:M1a(寡转移)=单器官转移或1至5个病灶;M1b=多器官转移或≥6个病灶。M1a和M1b的5年总生存率分别为38.7%和7.0%。

结论

寡转移患者的总生存期明显优于广泛转移患者。部分寡转移患者在接受全身化疗和根治性放疗后可实现长期无病生存。©2016威利期刊公司。《头颈》38:1152 - 1157,2016年。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验